And a growing number of therapeutic strategies were focused on TME, such as cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), and CTLA-4/PD-1/PD-L1 immune checkpoints (6–8). The gene discussed is CTLA4; the disease is neoplasm.